Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$93.86 USD

93.86
265,853

-1.64 (-1.72%)

Updated Aug 8, 2025 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mark Vickery headshot

Top Research Reports for Apple, Facebook & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Apple (AAPL), Facebook (FB) and AbbVie (ABBV).

Zacks Equity Research

Illumina (ILMN) Stock Moves -1.9%: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed the most recent trading day at $273, moving -1.9% from the previous trading session.

Zacks Equity Research

Why Is Illumina (ILMN) Down 12.2% Since Last Earnings Report?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kevin Cook headshot

Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD

by Kevin Cook

Do you know which investment whales were buying and selling your favorite stocks before the big rally to new highs?

Zacks Equity Research

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

by Zacks Equity Research

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Kevin Cook headshot

Coronavirus: How Fast to 100,000 Infected?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 6.92% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

Coronavirus: Epidemic or Pandemic?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Zacks Equity Research

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Zacks Equity Research

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Zacks Equity Research

Here's Why You Should Retain Pacific Biosciences Stock Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Zacks Equity Research

OSMT or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OSMT vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

ALXN vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

ALXN vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

by Zacks Equity Research

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.

Zacks Equity Research

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Zacks Equity Research

Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

Zacks Equity Research

EBS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

by Zacks Equity Research

Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.

Zacks Equity Research

Illumina (ILMN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 37.86% and 4.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?

by Zacks Equity Research

Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.